ConductScience.org, home

Library / Trials

Human Bioequivalence Study of Letermovir Tablets

NCT07922538, Phase 1, Completed, The Affiliated Hospital of Qingdao University

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleHuman Bioequivalence Study of Letermovir TabletsClinicalTrials.gov
NCT numberNCT07922538ClinicalTrials.gov
StatusCompletedClinicalTrials.gov
PhasesPhase 1ClinicalTrials.gov
Enrollment56 participants, actualClinicalTrials.gov
Lead sponsorThe Affiliated Hospital of Qingdao UniversityClinicalTrials.gov
ConditionsTmax*(h), Cmax(ng/mL), AUC0-t(ng∙h/mL), AUC0-∞(ng∙h/mL), λz(h-1), AUC_%Extrap(%)ClinicalTrials.gov
InterventionsGeneric Letermovir Tablet, Prevymis®ClinicalTrials.gov
First posted2026-11-06ClinicalTrials.gov
Last updated2026-11-06ClinicalTrials.gov

Registered outcomes 3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryMaximum Observed Plasma Concentration (Cmax) of LetermovirPre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-doseClinicalTrials.gov
PrimaryAUC0-t of LetermovirPre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-doseClinicalTrials.gov
PrimaryAUC0-inf of LetermovirPre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-doseClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)